Named among the 2016 Southern California Rising Stars for Securities and Corporate Finance by Super Lawyers Magazine

Richard Kim

Silicon Valley | San Francisco
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA
 
 

Richard Kim is a corporate associate in the Silicon Valley office of Latham & Watkins.

Mr. Kim advises public and private companies in the life sciences and technology industries. He also represents underwriters in securities offerings. His practice has a particular emphasis on capital markets matters, and he represents issuers and investment banks on various matters including initial public offerings and follow-on and secondary offerings.

His general company representation includes advising companies regarding securities law compliance and corporate governance matters.

Mr. Kim’s representative matters include representing:

  • Airbnb in its US$3.8 billion initial public offering
  • BofA Securities in connection with a US$222 million initial public offering of Janux Therapeutics
  • Jefferies in connection with a US$93 million initial public offering of Reneo Pharmaceuticals
  • Eventbrite in its US$150 million convertible senior notes offering and a subsequent US$212 million convertible senior notes offering
  • Airbnb in its US$2.0 billion convertible senior notes offering
  • Goldman Sachs & Co. in connection with a US$243 million initial public offering of PMV Pharmaceuticals
  • Annexon in its US$287 million initial public offering
  • Cantor Fitzgerald & Co. in connection with a US$20 million follow-on offering of Corium International
  • UBS Investment Bank, Canaccord Genuity, Stifel, and BTIG in connection with a US$75 million initial public offering of Obalon Therapeutics
  • Jefferies, Leerink Partners, and Wells Fargo Securities in connection with a US$32 million follow-on offering of Immune Design
  • JP Morgan, Cowen and Company, Stifel, Wells Fargo Securities, and SunTrust Robinson Humphrey in connection with a US$132 million follow-on offering of Array Biopharma
  • Piper Jaffray, Stifel, Leerink Partners, and William Blair in connection with a US$86 million initial public offering of Sientra
  • Piper Jaffray and William Blair in connection with a US$92 million following-on offering of LDR
  • JP Morgan, BofA Merrill Lynch, Goldman Sachs & Co., William Blair, and Cantor Fitzgerald & Co. in connection with a US$124 million initial public offering of Glaukos
  • BofA Merrill Lynch, JP Morgan, Morgan Stanley, Barclays, and Deutsche Bank Securities in connection with a US$911 million follow-on offering of BioMarin Pharmaceutical
  • JP Morgan, Leerink Partners, William Blair, and Stifel in connection with a US$72 million initial public offering of Inogen
  • BIND Therapeutics in its US$76 million initial public offering and subsequent public offerings
  • Aratana Therapeutics in its US$39 million initial public offering and several subsequent public offerings
  • Puma Biotechnology in its private placement and concurrent reverse merger into a public shell corporation and several public offerings
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.